Researchers have reported that nerandomilast, an investigational phosphodiesterase 4B (PDE4B) inhibitor, successfully reduced lung inflammation and fibrosis in preclinical models of idiopathic inflammatory myopathy–associated interstitial lung disease (IIM-ILD), a rare and often fatal condition for which treatment options remain severely limited. The findings mark a potentially significant step forward in the search for targeted therapies for IIM-ILD, a disease subset that carries high mortality rates and frequently proves resistant to existing immunosuppressive treatments. The results have drawn considerable attention from the rheumatology and pulmonology communities given the urgent unmet medical need in this patient population.
IIM-ILD is a serious pulmonary complication arising from idiopathic inflammatory myopathies, a group of autoimmune diseases that includes polymyositis, dermatomyositis, and antisynthetase syndrome. Interstitial lung disease develops in a significant proportion of IIM patients and is one of the leading causes of death within this population. Current treatment strategies, which primarily rely on corticosteroids and immunosuppressive agents, offer inconsistent results and carry substantial side effect profiles, underscoring the need for novel therapeutic approaches.
Nerandomilast works by selectively inhibiting PDE4B, an enzyme involved in regulating inflammatory signaling pathways in the lungs. In the experimental models studied, the drug demonstrated a measurable capacity to suppress key inflammatory mediators while simultaneously attenuating the fibrotic remodeling of lung tissue that characterizes progressive IIM-ILD. These dual effects — targeting both the inflammatory and fibrotic components of the disease — have positioned nerandomilast as a candidate with a potentially differentiated mechanism compared to existing therapies.
The preclinical data builds on broader research into nerandomilast's therapeutic profile, which has also been investigated in other fibrotic lung conditions, including idiopathic pulmonary fibrosis (IPF). The compound is being developed with the goal of providing a more targeted anti-inflammatory and antifibrotic treatment option that may offer improved tolerability over broader immunosuppressive regimens. Researchers noted that the selectivity of PDE4B inhibition, as opposed to pan-PDE4 inhibition, may help reduce the gastrointestinal side effects commonly associated with older drugs in this class.
While the preclinical results are considered promising, experts caution that further clinical trials will be necessary to confirm the drug's safety and efficacy in human patients with IIM-ILD. The translation from animal models to clinical outcomes in complex autoimmune and fibrotic diseases has historically presented challenges, and rigorous Phase II and Phase III studies will be required before any regulatory pathway can be pursued. Nevertheless, the current findings are expected to support the rationale for advancing nerandomilast into clinical investigation specifically targeting IIM-ILD populations.
